# Small Cell Lung Carcinoma trials: 213 new since Nov 2024

Updated November 5, 2026.

213 clinical studies in Small Cell Lung Carcinoma were first posted on ClinicalTrials.gov from November 21, 2024 to November 5, 2026; 98 have an industry sponsor and 187 are recruiting or about to. The newest, NCT07920549, was posted on November 5, 2026: A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage... (London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's).

## The full list

New Small Cell Lung Carcinoma clinical trials: 213 rows for $10.65, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 8 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/small-cell-lung-carcinoma

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 213
- Industry sponsored: 98
- Recruiting or not yet: 187
- Latest posted: November 5, 2026

## Newest trials

The newest 100 of 213, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07920549 | A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2/3 | Not yet recruiting | Limited Stage Small-Cell Lung Cancer | 150 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920549) |
| November 4, 2026 | NCT07914764 | 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis | Nanjing First Hospital, Nanjing Medical University | Observational | Recruiting | Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914764) |
| November 2, 2026 | NCT07909863 | Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909863) |
| November 2, 2026 | NCT07908667 | A Study of TRB191 in Patients With Extensive-stage Small Cell Lung Cancer | Novartis Pharmaceuticals | Phase 1 | Not yet recruiting | Extensive-stage Small Cell Lung Cancer | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908667) |
| November 2, 2026 | NCT07908537 | A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) | Merck Sharp & Dohme LLC | Phase 3 | Not yet recruiting | Small Cell Lung Cancer | 564 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908537) |
| October 30, 2026 | NCT07905937 | Exploration of Whole-Brain Radiotherapy Combined With PD-1 Inhibitors on Brain Injury | Guizhou Medical University | Observational | Recruiting | Small Cell Lung Cancer ( SCLC ), Brain Injury | 42 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905937) |
| October 23, 2026 | NCT07892625 | A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC | Hansoh BioMedical R&D Company | Phase 1 | Not yet recruiting | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 338 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892625) |
| October 23, 2026 | NCT07892300 | Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer | Oliver Jonas | Early phase 1 | Not yet recruiting | Lung Cancer, Mesothelioma, Suspected Lung Cancer, Suspected Mesothelioma | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892300) |
| October 22, 2026 | NCT07890246 | A Phase 1 Study of IM-1340 in Participants With Advanced Cancer | Immunome, Inc. | Phase 1 | Not yet recruiting | Colorectal Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Neoplasm | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890246) |
| October 21, 2026 | NCT07886047 | Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer | Second Xiangya Hospital of Central South University | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC) | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886047) |
| October 21, 2026 | NCT07885332 | Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer | Ruijin Hospital | Observational | Active not recruiting | Extensive-Stage Small Cell Lung Cancer | 26 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885332) |
| October 19, 2026 | NCT07881705 | A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With... | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Myelosuppression | 106 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881705) |
| October 15, 2026 | NCT07874581 | Effectiveness and Safety of MRG003 (Becotatug Vedotin) in Relapsed SCLC | Shanghai Pulmonary Hospital, Shanghai, China | Not applicable | Recruiting | Relapsed Small Cell Lung Cancer (SCLC) | 52 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874581) |
| October 7, 2026 | NCT07864207 | Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic) | IDP Discovery Pharma S.L. | Phase 1/2 | Recruiting | Small Cell Lung Cancer ( SCLC ) | 60 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864207) |
| September 28, 2026 | NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | Boehringer Ingelheim | Phase 1/2 | Recruiting | Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | 55 | Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843940) |
| September 15, 2026 | NCT07819591 | Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC | Shaodong Hong | Phase 2 | Not yet recruiting | SCLC, Recurrent | 47 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819591) |
| September 4, 2026 | NCT07803848 | Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor... | AIO-Studien-gGmbH | Phase 2 | Recruiting | Small-cell Lung Cancer | 57 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803848) |
| September 3, 2026 | NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih... | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Extensive-stage Small Cell Lung Cancer | 556 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802821) |
| September 2, 2026 | NCT07798947 | A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Limited-stage Small-cell Lung Cancer | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798947) |
| August 31, 2026 | NCT07796100 | A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint... | Zai Lab (Shanghai) Co., Ltd. | Phase 3 | Not yet recruiting | Extensive-Stage Small Cell Lung Cancer | 530 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796100) |
| August 31, 2026 | NCT07795411 | Prospective Multiomic Analysis in Small-Cell Lung Cancer | Ohio State University Comprehensive Cancer Center | Observational | Recruiting | Small Cell Cancer Of The Lung, Small Cell Lung Cancer ( SCLC ), Lung Cancer, Small-Cell Lung Cancer (SCLC) | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795411) |
| August 24, 2026 | NCT07783477 | A Study of Armored CAR T Cells in People With Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Neuroendocrine Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | 16 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783477) |
| August 21, 2026 | NCT07778316 | Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) | Amgen | Phase 3 | Recruiting | Small Cell Lung Cancer | 400 | Australia, China, Japan, Switzerland, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778316) |
| August 12, 2026 | NCT07759856 | NK Cells Plus ICI for SCLC Maintenance | Tianjin First Central Hospital | Phase 2 | Recruiting | Small Cell Lung Cancer | 42 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759856) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 4, 2026 | NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) | Anhui Provincial Cancer Hospital | Phase 4 | Recruiting | Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 107 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744698) |
| August 4, 2026 | NCT07744256 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Beijing Biotech | Phase 1/2 | Recruiting | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744256) |
| July 28, 2026 | NCT07730021 | A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic Solid Tumors | 392 | Japan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730021) |
| July 27, 2026 | NCT07728955 | A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as... | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Not yet recruiting | Small Cell Lung Cancer ( SCLC ) | 64 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728955) |
| July 20, 2026 | NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Treeline Biosciences, Inc. | Phase 1 | Recruiting | Small Cell Lung Cancer ( SCLC ), Neuroendocrine Cancer, Malignant Pleural Mesotheliomas (Mpm), Synovial Sarcomas | 120 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713732) |
| July 16, 2026 | NCT07707895 | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine... | Boehringer Ingelheim | Phase 1/2 | Not yet recruiting | Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell... | 60 | Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707895) |
| July 1, 2026 | NCT07677787 | DLL3-Targeted PET/CT in Small Cell Lung Cancer | The First Affiliated Hospital of Xiamen University | Not applicable | Recruiting | PET/CT, Small Cell Lung Cancer ( SCLC ), DLL3-targeted PET/CT, Delta-like Protein 3 | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677787) |
| June 26, 2026 | NCT07670442 | Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage... | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Small Cell Lung Cancer | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670442) |
| June 17, 2026 | NCT07654400 | A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | Biokin (Shanghai) Biopharmaceutical Co., Ltd. | Phase 2 | Recruiting | Extensive-stage Small-cell Lung Cancer | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654400) |
| June 17, 2026 | NCT07652736 | A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell... | BeOne Medicines | Observational | Recruiting | Advanced Non-Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer | 440 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652736) |
| June 12, 2026 | NCT07646106 | THE-0504 in Patients With Solid Tumors | Thena Biotech S.r.l. | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer... | 30 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646106) |
| June 11, 2026 | NCT07640932 | Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer | Yonsei University | Phase 2 | Not yet recruiting | Carcinoma, Small Cell Lung | 69 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640932) |
| June 9, 2026 | NCT07637513 | Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer | PrECOG, LLC. | Phase 3 | Not yet recruiting | Limited Stage Small-Cell Lung Cancer | 430 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637513) |
| June 9, 2026 | NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | Sun Yat-sen University | Phase 2/3 | Not yet recruiting | Small Cell Lung Cancer | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636226) |
| June 4, 2026 | NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | SystImmune Inc. | Phase 3 | Recruiting | Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung... | 550 | Australia, Bulgaria, Canada, Czechia, France, Georgia, Germany, Greece... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625644) |
| June 3, 2026 | NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or... | GV20 Therapeutics | Phase 2 | Not yet recruiting | Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and... | 227 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623642) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | Australia, China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| May 13, 2026 | NCT07583511 | Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study | Sun Yat-sen University | Phase 2 | Recruiting | Small-cell Lung Cancer | 90 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583511) |
| May 4, 2026 | NCT07565532 | Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment | Shanghai Chest Hospital | Observational | Recruiting | Small Cell Lung Cancer ( SCLC ), Radiotherapy, Immunotherapy, Personalized Cancer Treatment | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565532) |
| May 4, 2026 | NCT07564401 | A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy | Novartis Pharmaceuticals | Phase 1/2 | Recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 80 | Australia, Singapore, South Korea, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564401) |
| April 30, 2026 | NCT07559929 | A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1/2 | Recruiting | Small Cell Lung Cancer | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559929) |
| April 30, 2026 | NCT07559019 | Safety and Preliminary Activity of BI115 in Advanced SCLC | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC) | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559019) |
| April 29, 2026 | NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | Peking University First Hospital | Not applicable | Recruiting | Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer, Ovarian Cancer... | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557225) |
| April 27, 2026 | NCT07551635 | SMARCA4/2 Inhibitor for POU2F3-Positive SCLC | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Small Cell Lung Cancer | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551635) |
| April 24, 2026 | NCT07550842 | A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent... | Shanghai Best-Link Bioscience, LLC | Phase 1 | Not yet recruiting | Small Cell Carcinoma of Lung | 33 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550842) |
| April 24, 2026 | NCT07550049 | Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology | University of Kansas Medical Center | Observational | Not yet recruiting | Small Cell Lung Cancer, Head and Neck Cancer, Malignant Pleural Mesothelioma | 110 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07550049) |
| April 23, 2026 | NCT07548788 | A Lay Navigation Intervention for Patients With Lung Cancer | University Health Network, Toronto | Not applicable | Not yet recruiting | Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC), Patient Navigation | 50 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548788) |
| April 23, 2026 | NCT07547332 | Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 | Not yet recruiting | Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 84 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07547332) |
| April 22, 2026 | NCT07545954 | DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer | Washington University School of Medicine | Phase 1 | Recruiting | Small-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545954) |
| April 20, 2026 | NCT07538271 | A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer | Yayi He | Phase 2 | Not yet recruiting | SCLC, Extensive Stage | 33 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538271) |
| April 20, 2026 | NCT07538258 | Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer | Yayi He | Phase 2 | Not yet recruiting | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 27 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538258) |
| April 17, 2026 | NCT07535359 | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer | Daiichi Sankyo | Not applicable | No longer available | SCLC, Extensive-stage Small Cell Lung Cancer | Not listed | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07535359) |
| April 15, 2026 | NCT07532057 | Pulmonary Rehabilitation During Chemotherapy in Stage IIIB/IV Small Cell Lung Cancer | Istanbul Medipol University Hospital | Not applicable | Completed | Cancer, Lung Neoplasms, Lung Cancer Small Cell Lung Cancer (SCLC) | 30 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532057) |
| April 15, 2026 | NCT07531095 | Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) | Amgen | Phase 1 | Recruiting | Small Cell Lung Cancer | 160 | Australia, Belgium, France, Germany, Poland, Spain, Switzerland, Turkey... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07531095) |
| April 14, 2026 | NCT07529145 | Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment | Medical University of Bialystok | Observational | Recruiting | Non-Small Cell Carcinoma of Lung, Small Cell Carcinoma of Lung | 90 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529145) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| April 3, 2026 | NCT07510724 | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Observational | Recruiting | Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer (Diagnosis) | 240 | Austria, Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510724) |
| April 3, 2026 | NCT07509333 | MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients | West China Hospital | Not applicable | Recruiting | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma | 2,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509333) |
| April 3, 2026 | NCT07509034 | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Small Cell Lung Cancer, Small Cell Lung... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509034) |
| April 2, 2026 | NCT07508852 | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer | Peking University First Hospital | Phase 1/2 | Recruiting | SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ) | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508852) |
| March 30, 2026 | NCT07502300 | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Extensive-stage Small-cell Lung Cancer | 562 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502300) |
| March 30, 2026 | NCT07501169 | Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Sichuan University | Phase 2 | Not yet recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 33 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501169) |
| March 24, 2026 | NCT07489339 | MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy | Shanxi Province Cancer Hospital | Not applicable | Completed | Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer, Lung Neoplasms | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489339) |
| March 23, 2026 | NCT07488923 | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC... | Moonlight Bio, Inc | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC)... | 110 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488923) |
| March 23, 2026 | NCT07488676 | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma | 150 | Japan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488676) |
| March 20, 2026 | NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage... | The Affiliated Hospital of Qingdao University | Phase 4 | Not yet recruiting | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485920) |
| March 18, 2026 | NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Beijing Biotech | Phase 1/2 | Recruiting | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480213) |
| March 17, 2026 | NCT07476287 | Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With... | Pfizer | Phase 2 | Recruiting | Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma... | 40 | Australia, Brazil, China, France, Hong Kong, India, Israel, Italy, Japan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476287) |
| March 16, 2026 | NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | Shanghai JMT-Bio Inc. | Phase 1/2 | Not yet recruiting | Non-Small Cell Lung Cancer, Small Cell Lung Cancer | 596 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472647) |
| March 16, 2026 | NCT07472517 | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and... | Boehringer Ingelheim | Phase 3 | Recruiting | Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 670 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472517) |
| March 12, 2026 | NCT07468656 | SCLC Tarlatamab Blood Collection | Duke University | Observational | Not yet recruiting | Small-cell Lung Cancer | 25 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468656) |
| March 12, 2026 | NCT07465757 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) | Puma Biotechnology, Inc. | Phase 2 | Recruiting | Small Cell Lung Cancer ( SCLC ) | 50 | France, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465757) |
| March 10, 2026 | NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | Jazz Pharmaceuticals | Phase 2 | Recruiting | Extensive-stage Small-cell Lung Cancer | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07459634) |
| March 6, 2026 | NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors | Avacta Life Sciences Ltd | Phase 1 | Recruiting | Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical... | 174 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07454642) |
| February 25, 2026 | NCT07434518 | A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Observational | Recruiting | Small Cell Lung Cancer (SCLC) | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07434518) |
| February 20, 2026 | NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | Conjupro Biotherapeutics, Inc. | Phase 1 | Recruiting | Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer | 386 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424547) |
| February 20, 2026 | NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | Asrar Alahmadi | Phase 2 | Recruiting | Extensive Stage Lung Small Cell Carcinoma | 39 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423585) |
| February 17, 2026 | NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell... | Shanghai Best-Link Bioscience, LLC | Phase 1/2 | Not yet recruiting | Small Cell Carcinoma of Lung | 48 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07414927) |
| February 12, 2026 | NCT07407933 | A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | MediLink Therapeutics (Suzhou) Co., Ltd. | Phase 1/2 | Recruiting | Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | 118 | Belgium, France, Hungary, Italy, Poland, Romania, Spain, United Kingdom, United... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407933) |
| February 11, 2026 | NCT07402343 | Tarlatamab for SCLC Brain Metastases | Maastricht University Medical Center | Phase 2 | Recruiting | Small Cell Lung Cancer, Brain Metastases, Adult | 35 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07402343) |
| February 10, 2026 | NCT07398560 | Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An... | The Third Affiliated Hospital of Harbin Medical University | Phase 2 | Not yet recruiting | Small Cell Lung Cancer | 47 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398560) |
| February 6, 2026 | NCT07391670 | A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab | AstraZeneca | Phase 1 | Recruiting | Solid Tumours | 40 | Australia, Georgia, Poland, South Korea, Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391670) |
| February 5, 2026 | NCT07390565 | YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer | LI FENG | Not applicable | Enrolling by invitation | Extensive-stage Small Cell Lung Cancer (SCLC) | 308 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390565) |
| February 5, 2026 | NCT07388875 | Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC | China Medical University, China | Phase 2 | Not yet recruiting | Extensive-Stage Small Cell Lung Cancer | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07388875) |
| February 3, 2026 | NCT07383454 | Lung Cancer Screening in Population Who Had Never Smoked | Chung Shan Medical University | Not applicable | Not yet recruiting | Lung Cancer (Diagnosis), Non-Small Cell Lung Cancer, Small Cell Carcinoma of Lung, Screening Strategy | 2,500 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07383454) |
| January 29, 2026 | NCT07376499 | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune... | China Medical University, China | Phase 2 | Not yet recruiting | Small Cell Lung Cancer | 31 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376499) |
| January 28, 2026 | NCT07373964 | A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor... | China Medical University, China | Phase 2 | Recruiting | Small Cell Lung Cancer | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07373964) |
| January 26, 2026 | NCT07365241 | A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants... | AbbVie | Phase 3 | Recruiting | Small Cell Lung Cancer | 531 | Austria, Belgium, Brazil, France, Germany, Greece, Japan, Spain, Switzerland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365241) |
| January 22, 2026 | NCT07358676 | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358676) |
| January 22, 2026 | NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Small Cell Lung Carcinoma | 44 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07357532) |
| January 14, 2026 | NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | Bindu R Potugari | Phase 2 | Recruiting | Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 35 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339059) |
| January 9, 2026 | NCT07328490 | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage... | National Cancer Institute (NCI) | Phase 1/2 | Withdrawn | Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma | 0 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07328490) |
| January 8, 2026 | NCT07325136 | A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small... | Bristol-Myers Squibb | Phase 1/2 | Recruiting | Relapsed/Refractory Small Cell Lung Cancer | 240 | China, Italy, Japan, Romania, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07325136) |
| January 5, 2026 | NCT07316309 | CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer | Shandong Cancer Hospital and Institute | Observational | Completed | Small Cell Lung Cancer | 33 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07316309) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Shanghai Pulmonary Hospital, Shanghai, China | 5 | October 15, 2026 |
| Amgen | 5 | August 21, 2026 |
| Peking University Cancer Hospital & Institute | 5 | January 22, 2026 |
| Novartis Pharmaceuticals | 4 | November 2, 2026 |
| Sun Yat-sen University | 4 | June 9, 2026 |
| AstraZeneca | 4 | February 6, 2026 |
| China Medical University, China | 4 | February 5, 2026 |
| Tianjin Medical University Cancer Institute and Hospital | 3 | November 2, 2026 |
| Boehringer Ingelheim | 3 | September 28, 2026 |
| Qilu Pharmaceutical Co., Ltd. | 3 | September 3, 2026 |
| Memorial Sloan Kettering Cancer Center | 3 | August 24, 2026 |
| Shanghai Chest Hospital | 3 | May 4, 2026 |
| Sichuan University | 3 | March 30, 2026 |
| AbbVie | 3 | January 26, 2026 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 3 | November 17, 2025 |
| Peking Union Medical College Hospital | 3 | September 15, 2025 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2 | November 5, 2026 |
| Merck Sharp & Dohme LLC | 2 | November 2, 2026 |
| Hansoh BioMedical R&D Company | 2 | October 23, 2026 |
| Zai Lab (Shanghai) Co., Ltd. | 2 | August 31, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 61 | November 2, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 37 | November 2, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 32 | November 4, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 32 | October 7, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 24 | November 2, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 15 | October 15, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 4 | November 5, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 4 | October 23, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 4 | August 4, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 108 | November 4, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 65 | September 28, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 27 | October 7, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 21 | September 28, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 20 | September 28, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 20 | September 28, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 19 | June 12, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 17 | September 28, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 15 | June 11, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 14 | September 28, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 11 | April 15, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 10 | September 28, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 10 | July 16, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 9 | November 5, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 9 | June 4, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 9 | March 17, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 7 | September 28, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 7 | August 21, 2026 |
| [Hungary](https://specstream.ai/data/clinical-trials/country/hungary) | 6 | June 4, 2026 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 6 | April 3, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 6 | March 17, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 6 | March 17, 2026 |
| [Romania](https://specstream.ai/data/clinical-trials/country/romania) | 6 | March 16, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 5 | March 16, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 4 | June 4, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).